Furthermore, liver-specific targeting of CerS6 to reduce hepatic C16:0 ceramide synthesis in obesity can even reverse the detrimental effects of obesity on mitochondrial morphology and glucose metabolism, highlighting the therapeutic potential of CerS6 inhibition to treat obesity-associated hepatic and systemic defects [26]. Here, CERS6 is linked to obesity due to melanocortin 4 receptor deficiency.